Syntax Research Inc. Makes New $712,000 Investment in Intuitive Surgical, Inc. $ISRG

Posted by Sarita Garza on Nov 10th, 2026

Syntax Research Inc. acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,751 shares of the medical equipment provider’s stock, valued at approximately $712,000. Intuitive Surgical comprises about 0.5% of Syntax Research Inc.’s investment portfolio, making the stock its 27th largest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Bank of New York Mellon Corp purchased a new stake in shares of Intuitive Surgical in the second quarter valued at about $1,335,753,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after buying an additional 1,027,475 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Intuitive Surgical by 55.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,557,940 shares of the medical equipment provider’s stock worth $633,505,000 after buying an additional 558,099 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Intuitive Surgical during the third quarter worth about $136,743,000. Finally, Amundi grew its holdings in shares of Intuitive Surgical by 8.6% during the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after buying an additional 193,096 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Up 1.7%

NASDAQ:ISRG opened at $460.56 on Tuesday. The firm’s fifty day simple moving average is $411.69 and its 200-day simple moving average is $431.58. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The stock has a market cap of $159.65 billion, a PE ratio of 55.69, a price-to-earnings-growth ratio of 3.32 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last issued its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. During the same period last year, the company posted $2.40 earnings per share. The firm’s quarterly revenue was up 21.7% compared to the same quarter last year. Equities analysts anticipate that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several analyst reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $486.00 price objective (down from $487.00) on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Citigroup lowered their target price on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a research note on Friday, July 17th. UBS Group reissued a “buy” rating on shares of Intuitive Surgical in a report on Tuesday, October 13th. Finally, BNP Paribas Exane upgraded Intuitive Surgical to an “outperform” rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $493.54.

Check Out Our Latest Report on ISRG

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Revenue grew 22%, and the company placed 546 da Vinci systems in the third quarter of 2026. The article notes that system placements support a larger installed base, while instruments and services generate much of Intuitive Surgical’s recurring revenue. Intuitive Surgical Placed 546 da Vinci Systems Last Quarter. Why Wall Street’s Sell-Off Misses the Point.
Positive Sentiment: Robust procedure growth and adoption of the da Vinci 5 system have helped shares recover, according to a six-month review. ISRG Gains 7.8% in 6 Months: Will the Share Price Recovery Continue?
Neutral Sentiment: Intuitive Surgical appeared on a published list of top healthcare stocks following the midterm elections. The inclusion reflects investor interest in the sector, but is not a company-specific business development. Why Intuitive Surgical (ISRG) Just Cracked the Top 10 Best Healthcare Stocks List
Negative Sentiment: Growing competition, litigation costs and valuation concerns could weigh on the shares. One article also notes that ISRG remains down for the year despite strong revenue growth. Intuitive Surgical (ISRG) Just Grew Revenue 22%. Why Is the Stock Still Down This Year?

Insiders Place Their Bets

In related news, SVP Patricia Wadors sold 1,078 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total value of $478,416.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $457.34, for a total value of $4,573,400.00. Following the completion of the transaction, the director directly owned 1,194,530 shares of the company’s stock, valued at $546,306,350.20. The trade was a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 39,056 shares of company stock worth $17,585,864. 0.60% of the stock is owned by insiders.